Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label gantenerumab rollover study in Alzheimer's disease
2019-004431-23Phase 3Completed
- Sponsor
- Roche
- Start
- Feb 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of gantenerumab in Alzheimer's disease (AD), sponsored by Roche. Primary endpoint: Incidence, nature, severity, and timing of adverse events and serious adverse events. Started Feb 2020; status: completed.
02
Drugs
gantenerumab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2019-004431-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004431-23.